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In patients with ST-segment elevation myocardial infarction (STEMI), when
percutaneous coronary intervention is not an option, reperfusion therapy with the
fibrinolytic agents tenecteplase, reteplase, or accelerated alteplase (90 minutes of
infusion) plus parenteral anticoagulation has better overall safety and efficacy than
other regimens.DS
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Fibrinolytic Regimen
All-Cause Mortality
Within 30 to 35 Days,
RR (95% CI)
Major Bleeding,
RR (95% CI)
Acc tPAþPAC 1.0 [Reference] 1.0 [Reference]
TNKþPAC 1.01 (0.90–1.13) 0.79 (0.63–1.00)
rPAþPAC 1.04 (0.94–1.15) 0.88 (0.69–1.12)
SKþPAC 1.14 (1.05–1.24) 0.92 (0.70–1.21)
tPAþPAC 1.26 (1.10–1.45) 0.63 (0.44–0.92)
RR, Relative risk; CI, confidence interval; Acc tPA, accelerated alteplase infusion during 90 minutes (guideline
recommended); PAC, parenteral anticoagulants; TNK, tenecteplase; rPA, reteplase; SK, streptokinase; tPA,
nonaccelerated alteplase infusion during 3 hours.
*RR greater than 1.0 tends toward more deaths and bleeding.Forty studies met inclusion criteria,
involving 128,071 STEMI patients
treated with 12 fibrinolytic regi-
mens. Four fibrinolytic agents
(streptokinase, reteplase, ten-
ecteplase, and alteplase at 2 sepa-
rate dosing regimens)
were compared as reperfusion published in final edited form as:
18). In Patients With ST-Segment Elevation Myo
ergency Medicine.  https://doi.org/10.1016/j.anntherapy alone or in combination
with antithrombotic agents,
including parenteral anticoagulants
(ie, low-molecular-weight heparin,
heparin, anti-Xa inhibitor, and
direct thrombin inhibitor) or
glycoprotein IIb or IIIa inhibitors
(ie, abciximab, tirofiban, orAnnals of Emergency Medicine 1
cardial Infarction, Which Fibrinolytic Agent Is 
emergmed.2018.01.042
Heterogeneity was determined
with the Cochran Q test and I2
statistic. A network meta-analysis
with consistency model compared
intervention data. Evidence
quality was assessed with the
Grading of Recommendations
Assessment, Development and
Evaluation.
Systematic Review Snapshoteptifibatide) (Table). Thirty-six tri-
als specified that aspirin was a part
of therapy. Thirty-nine studies
assessed all-cause mortality and 32
reported major bleeding. In terms
of bias, 27 studies had an unclear
risk bias, with 13 having high risk of
bias at least 1 category ofmasking of
participants or personnel (6
studies), masking of outcome as-
sessments (1 study), selective
outcome reporting (2 studies), and
other bias (6 studies).
Commentary
Timely reperfusion therapy is
essential for successful manage-
ment of STEMI.1 Thrombolysis
plays a significant role when
access to percutaneous coronary
intervention is limited or not
available in a timely manner,
particularly in rural settings or
low- and middle-income countries
in which percutaneous coronary
intervention is not available.2 With
risks of bleeding, stroke, and
intracranial hemorrhage, use of
the most effective and safest
fibrinolytic regimen is critical.3,4
This systematic review found that
in STEMI patients, tenecteplase,
reteplase, and accelerated alte-
plase (90-minute infusion) plus
parenteral anticoagulation were
the most effective regimens (ie,
lower mortality), with an accept-
able safety profile (ie, lower risk of
bleeding), compared with2 Annals of Emergency Medicinestreptokinase or nonaccelerated
alteplase with or without
parenteral anticoagulation. The
network meta-analysis showed
that monotherapy fibrinolytics
(streptokinase and nonaccelerated
alteplase) had increased risk of
mortality compared with
guideline-recommended acceler-
ated alteplase with parenteral
anticoagulation. The addition of
glycoprotein IIb or IIIa inhibitors
to any fibrinolytic regimen signifi-
cantly increased the risk of major
bleeding and therefore should be
avoided.
For clinicians with limited access
to percutaneous coronary inter-
vention, tenecteplase or reteplase
with parenteral anticoagulation is
as safe and effective as accelerated
alteplase with parenteral anti-
coagulation and offers the addi-
tional advantage of a longer half-
life, making it easier to admin-
ister as a single intravenous bolus
injection. Alteplase has a short
half-life and requires a bolus, fol-
lowed by an infusion. The single-
bolus options may be advanta-
geous when treatment must be
initiated before a long transport
time to a percutaneous coronary
intervention center. With these 3
regimens available, non-
accelerated alteplase and strepto-
kinase should be avoided because
of associated higher mortality
rates. However, because of cost,
streptokinase continues to be used
extensively as the primary treat-
ment for STEMI in low-
and middle-income countries.
Although studies in the United
States have shown alteplase to be
more cost-effective than strepto-
kinase, further cost-effective ana-
lyses in low- and middle-income
countries may help demonstrate
the benefit needed to advocateavailability of more effective,
safer fibrinolytic regimens.5 As
cardiovascular deaths increase
globally, implementing guidelines
using fibrinolytic regimens that
maximize safety and decrease
harm is important to improving
global emergency care for STEMI.6
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